Fredun Pharmaceuticals Reports Stellar Q1 FY27 Performance; Revenue Jumps 90%, Profit Rises 95% YoY
Mumbai, August 6, 2026 — Fredun Pharmaceuticals Limited, a major pharmaceutical formulation manufacturing company in India, has announced its unaudited financial results for the first quarter (Q1) of Fiscal Year 2027 (FY27). The Company offers a diversified portfolio that encompasses generics, nutraceuticals, cosmeceuticals, mobility solutions, and animal healthcare products.The Q1 FY27 results highlight robust growth across key performance indicators, as detailed in the financial summary below:
| Particulars ( ₹ Cr) | Q1 FY27 | Q1 FY26 | YoY Growth |
|---|---|---|---|
| Total Income | 228.25 | 119.86 | 90.44% |
| EBITDA | 32.78 | 16.99 | 92.90% |
| EBITDA Margin (%) | 14.36% | 14.18% | 18 Bps |
| Net Profit | 13.17 | 6.77 | 94.63% |
| Net Profit margin (%) | 5.77% | 5.64% | 12 Bps |
| EPS Basic ( ₹ ) | 23.89 | 14.33 | 66.71% |
Management Comments on Growth Trajectory
Commenting on the strong financial performance, Mr. Fredun Medhora, Managing Director of Fredun Pharmaceuticals Limited, stated that Q1 FY27 establishes a solid foundation for the fiscal year."The quarter reinforces our belief that the long-term investments made across the business are starting to translate into tangible results," Medhora said. "We have consistently focused on building a diversified healthcare company with multiple growth engines rather than chasing short-term gains."
He added that as the Company continues to expand its branded portfolio and strengthen manufacturing capabilities, it is laying the groundwork for future expansion. Medhora expressed optimism about the evolving healthcare sector, noting that specialized therapies and preventive solutions are creating significant market demand.
Key Business Updates and Overview
Fredun Pharmaceuticals Limited specializes in a range of products including antihypertensives, antidiabetic, antiretroviral drugs (ARVs), and narcotics. The Company is also active in manufacturing dietary/herbal supplements, nutraceuticals, cosmeceuticals, and animal healthcare items, aiming to be a holistic healthcare provider. Its primary export markets include Africa, Southeast Asia, the Commonwealth of Independent States (CIS) countries, and Latin America.Earlier financial context shows that in FY26, Fredun reported total revenues of ₹ 639.12 Cr, with an EBITDA of ₹ 94.79 Cr and a Profit After Tax (PAT) of ₹ 33.21 Cr.
In other corporate news, the Company announced the allotment of Bonus Equity Shares to eligible shareholders on July 17, 2026, at a ratio of 2:1. Following this bonus allotment, the issued and paid-up equity share capital increased from 55.13 lakh shares to 1.65 crore shares.
Stock Price Movement
Fredun Pharmaceuticals Ltd shares settled on Thursday at ₹1221.80, sinking 6.97%. The stock experienced volatility throughout the day, trading between a low of ₹1201.00 and an intraday high of ₹1331.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.